抗體-siRNA 藥物偶聯物市場（按目標抗體類型、偶聯化學、給藥途徑、最終用戶和治療領域）—2025-2030 年全球預測

抗體-siRNA藥物偶聯物市場預計在2024年價值為11.3億美元，在2025年成長至12.5億美元，到2030年達到21.4億美元，複合年成長率為11.14%。

主要市場統計數據
基準年2024年	11.3億美元
預計2025年	12.5億美元
預測年份 2030	21.4億美元
複合年成長率（%）	11.14%

利用創新抗體-siRNA藥物偶聯物徹底改變精準醫療，實現下一代疾病干預

抗體標靶與小干擾RNA (siRNA)有效載荷的整合標誌著精準醫療發展的一個分水嶺。這些複雜的構建體利用抗體結合域的精準特異性，將基因靜默分子直接護送至患病細胞，從而減輕全身暴露並降低脫靶效應。受成熟抗體藥物複合體成功的啟發，這種新一代模式融合了兩種成熟的技術，以應對長期以來限制核酸療法發展的挑戰。

抗體-siRNA 偶聯物的出現正在重新定義現代生物製藥創新中的標靶遞送和治療效果

隨著抗體-siRNA偶聯物越來越受到研究人員和開發者的認可，標靶治療領域正在經歷重大變革。這項變革的核心是位點特異性偶聯技術的成熟，該技術能夠確保藥物的均勻分佈和可預測的藥物動力學。因此，該行業正在從非均相混合物轉向高度精準的分子實體，從而提高療效和安全性。

探討美國新實施的關稅對2025年全球抗體-siRNA藥物偶聯物供應鏈的累積影響

美國對關鍵原料和生產設備徵收新關稅，對抗體-siRNA藥物偶聯物供應鏈既構成挑戰，也構成策略曲折點。特殊脂質、寡核苷酸前驅和生物反應器組件的關稅上調增加了投入成本，促使製造商重新考慮籌資策略，並實現供應商多元化。因此，他們正在調整生產結構，以緩解關稅帶來的利潤壓縮。

揭示推動抗體-siRNA 藥物偶聯物在不同細分市場開發和應用的關鍵細分模式

仔細研究市場細分，可以深入了解推動抗體-siRNA偶聯物應用的因素。根據標靶抗體的類型分析，可以發現三大類：抗體片段、雙特異性抗體和單株抗體。在抗體片段類別中，Fab 和 scFv 變異體在組織滲透和有效載荷方面具有獨特優勢，可廣泛應用於從腫瘤學到神經系統疾病等各種疾病。

繪製區域動態圖顯示，美洲、歐洲、中東和非洲地區以及亞太地區各自推動不同的抗體-siRNA 藥物偶聯生態系統

區域動態在塑造抗體-siRNA藥物偶聯物生態系統中發揮至關重要的作用。美洲擁有大型生物製藥中心，這些中心加上強大的法律規範和創業投資的湧入，正在促進產品線的快速發展。該地區的產學合作正在加速轉化研究，以前所未有的速度將候選化合物從實驗室推進到早期臨床評估。

塑造抗體-siRNA藥物偶聯物開發和商業化未來的關鍵創新者的策略舉措和競爭格局

抗體-siRNA 偶聯物開發的競爭格局由成熟生物製藥公司和新興生物技術公司的策略性舉措決定。領先的創新者正在夥伴關係，將其專有的抗體支架與專門的RNA干擾平台結合。這些合作涵蓋技術許可、共同開發契約和合資企業，體現了加快臨床開發和擴大治療範圍的共同努力。

產業領導者在加速抗體-siRNA藥物偶聯物開發平臺的商業性成功和創新方面面臨的策略挑戰

產業領導者必須優先考慮其開發框架的敏捷性，以充分利用不斷發展的抗體-siRNA偶聯物範式。從一開始就建立整合製程開發、分析科學和法規事務的跨職能團隊，可以簡化里程碑交付並降低轉換風險。將模組化偶聯平台整合到現有的生技藥品研發管線中，可以幫助企業利用現有的生產基礎設施，加速商業化進程。

嚴格的多模態調查方法，整合主要專家訪談和二手資料來源，提供抗體-siRNA 結合物市場的全面視角

本分析所採用的調查方法全面整合了原始資料和二手資料，以確保研究的嚴謹性和有效性。原始資料是透過與生物技術公司、委外研發機構和監管專家的高級管理人員進行結構化訪談收集的。這種定性研究有助於深入了解偶聯平台、開發挑戰以及整個價值鏈的策略重點。

關於抗體-siRNA藥物偶聯物治療領域的變革潛力、策略途徑和新興機會的結論

抗體-siRNA藥物偶聯物是兩種創新治療技術的結合，為疾病介入提供了一種協同方法，突破了單一治療方法的限制。它們能夠遞送強效的基因阻斷有效載荷，並具有抗體水平的特異性，使其成為一個多功能平台，能夠滿足多種尚未滿足的治療需求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

• 腫瘤靶向抗體的進展提高了固態腫瘤中 siRNA 的傳遞效率
• 新興雙負載抗體-siRNA偶聯物可對抗多重抗藥性癌細胞
• 最佳化接頭技術以提高抗體-siRNA複合物的穩定性和釋放特性
• 整合生物分解性聚合物載體用於ADC平台中siRNA的控制釋放
• 利用低溫電子顯微鏡結構分析合理設計抗體-siRNA結合位點
• 開發雙特異性抗體，用於將 siRNA 和免疫調節劑共同遞送至腫瘤微環境
• 核內體逃脫策略的進展增強了胞質 siRNA 在 ADC 治療中的可用性
• 抗體-siRNA複合物的標準化表徵和安全測試的監管指南不斷發展
• 利用人工智慧預測抗體-siRNA 藥物的最佳結合位點
• 生技公司與製藥公司之間的策略合作加速了抗體-siRNA 偶聯物的臨床研發

第6章 市場洞察

• 波特五力分析
• PESTEL分析

第7章 2025年美國關稅的累積影響

8. 抗體-siRNA 藥物偶聯物市場（以目標抗體類型）

• 抗體片段
  • Fab
  • scFv
• 雙特異性抗體
• 單株抗體

9. 抗體-siRNA 藥物偶聯物市場（依偶聯化學）

• 可裂解接頭
• 不可切割的連接子
• 位點特異性結合

10. 抗體-siRNA藥物偶聯物市場（依給藥途徑）

• 靜脈注射（IV）
• 皮下（SC）

第 11 章：抗體-siRNA 藥物偶聯物市場（依最終用戶）

• 生技公司
• 合約研究組織
• 製藥公司

12. 抗體-siRNA藥物偶聯物市場（依治療領域）

• 遺傳性疾病
  • 常見遺傳疾病
  • 罕見遺傳疾病
• 感染疾病
  • 細菌感染疾病
  • 病毒感染
• 神經系統疾病
• 腫瘤學
  • 造血系統惡性腫瘤
  • 固態腫瘤

13. 美國抗體-siRNA藥物偶聯物市場

• 美國
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

14. 歐洲、中東和非洲抗體-siRNA藥物偶聯物市場

• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 阿拉伯聯合大公國
• 沙烏地阿拉伯
• 南非
• 丹麥
• 荷蘭
• 卡達
• 芬蘭
• 瑞典
• 奈及利亞
• 埃及
• 土耳其
• 以色列
• 挪威
• 波蘭
• 瑞士

15. 亞太地區抗體-siRNA藥物偶聯物市場

• 中國
• 印度
• 日本
• 澳洲
• 韓國
• 印尼
• 泰國
• 菲律賓
• 馬來西亞
• 新加坡
• 越南
• 台灣

第16章競爭格局

• 2024年市場佔有率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • AbbVie Inc.
  • Avidity Biosciences Inc.
  • Biointron Biological Inc.
  • CD Bioparticles
  • Dyne Therapeutics, Inc.
  • Sirnaomics, Inc.
  • Tallac Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals Inc.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

The Antibody-siRNA Drug Conjugates Market was valued at USD 1.13 billion in 2024 and is projected to grow to USD 1.25 billion in 2025, with a CAGR of 11.14%, reaching USD 2.14 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 1.13 billion
Estimated Year [2025]	USD 1.25 billion
Forecast Year [2030]	USD 2.14 billion
CAGR (%)	11.14%

Revolutionizing Precision Therapeutics through Innovative Antibody-siRNA Drug Conjugates for Next-Generation Disease Intervention

The integration of antibody targeting with small interfering RNA (siRNA) payloads represents a watershed moment in the evolution of precision medicine. These sophisticated constructs leverage the exquisite specificity of antibody binding domains to escort gene-silencing molecules directly into diseased cells, mitigating systemic exposure and reducing off-target effects. Drawing inspiration from the successes of established antibody-drug conjugates, this next-generation modality marries two proven technologies to address challenges that have long constrained nucleic acid therapeutics.

By harnessing receptor-mediated internalization pathways, antibody-siRNA conjugates navigate biological barriers that once hindered effective delivery of RNA-based drugs. As a result, patient populations affected by malignancies, inherited disorders, viral infections, and neurological conditions are now within reach of treatments offering unprecedented target selectivity. Early-stage research and emerging clinical case studies underscore the potential for deep molecular knockdown, durable gene silencing, and a favorable safety profile in settings where conventional modalities fall short.

Moreover, continuous advancements in linker design and conjugation chemistries are enhancing the stability, potency, and manufacturability of these dual-function agents. This technological momentum is complemented by growing collaborations among academic institutions, biotech innovators, and contract research organizations, all contributing to the refinement of scalable processes and regulatory frameworks. Ultimately, the antibody-siRNA drug conjugate platform signals a transformative leap toward personalized therapeutics, poised to redefine treatment paradigms across a broad spectrum of diseases.

Emergence of Antibody-siRNA Conjugates Redefining Targeted Delivery and Therapeutic Efficacy in Modern Biopharmaceutical Innovation

The landscape of targeted therapeutics is undergoing a profound metamorphosis as antibody-siRNA conjugates gain traction among researchers and developers. Central to this evolution is the maturation of site-specific conjugation techniques, which ensure uniform payload distribution and predictable pharmacokinetics. Consequently, the industry is witnessing a shift away from heterogeneous mixtures toward highly defined molecular entities with improved efficacy and safety margins.

Equally transformative is the emergence of cleavable linker technologies that facilitate controlled release of siRNA payloads upon cellular uptake. This precision release mechanism not only enhances gene silencing efficiency but also mitigates premature degradation in circulation. In parallel, non-cleavable linkers are being refined to bolster intracellular retention, thereby extending the duration of therapeutic activity at target sites. The convergence of these linker strategies has catalyzed a wave of pipeline diversification.

In regulatory circles, agencies are beginning to articulate guidance frameworks tailored to the unique characteristics of antibody-nucleic acid conjugates. As a result, clarity around quality attributes, bioanalytical testing, and safety evaluation is improving, accelerating both preclinical validation and first-in-human trials. Furthermore, collaborative consortia are fostering data sharing and establishing consensus on critical development milestones, streamlining the pathway from proof-of-concept to market entry.

Overall, the industry's embrace of innovative conjugation platforms, coupled with proactive regulatory engagement, is redefining the benchmarks for targeted delivery. These transformative shifts are equipping developers with the tools to tackle previously intractable therapeutic targets and laying the groundwork for a new generation of precision medicines.

Exploring the Cumulative Impact of Newly Implemented United States Tariffs on Global Antibody-siRNA Drug Conjugate Supply Chains into 2025

The implementation of newly enacted United States tariffs on key raw materials and manufacturing equipment has introduced both challenges and strategic inflection points within the antibody-siRNA drug conjugate supply chain. Higher duties on specialty lipids, oligonucleotide precursors, and bioreactor components have elevated input costs, prompting manufacturers to reexamine procurement strategies and supplier diversification. Consequently, production frameworks are being restructured to mitigate tariff-induced margin compression.

Additionally, the ripple effects of these trade measures extend to contract research organizations that provide analytical testing, conjugation services, and formulation optimization. With increased operational expenditures, many service providers are recalibrating project timelines and revising pricing models, leading to a dynamic landscape in which cost efficiency and value-added capabilities are paramount. In response, industry stakeholders are exploring nearshoring opportunities to reduce import exposure and enhance supply chain resilience.

Moreover, continuous dialog with regulatory bodies and trade associations has become instrumental in navigating tariff classifications and securing potential exemptions for research-critical materials. These advocacy efforts underscore the importance of collaborative engagement in shaping policy interpretations that support innovation without compromising fiscal objectives. Simultaneously, companies are investing in vertical integration initiatives to internalize key conjugation processes and shield strategic capabilities from external cost volatility.

Ultimately, the cumulative impact of these tariffs is driving a strategic recalibration across the antibody-siRNA conjugate arena. By fostering supply chain agility, cultivating alternative sourcing arrangements, and deepening regulatory partnerships, organizations can transform tariff pressures into a catalyst for operational excellence and sustained competitive advantage.

Uncovering Critical Segmentation Patterns That Drive Development and Adoption of Antibody-siRNA Drug Conjugates across Diverse Market Niches

A granular examination of market segmentation reveals profound insights into the drivers of antibody-siRNA conjugate adoption. When analyzed by target antibody type, three primary classes emerge: antibody fragments, bispecific antibodies, and monoclonal antibodies. Within the antibody fragment category, the Fab and scFv variants provide distinct advantages in tissue penetration and payload loading, catering to applications ranging from oncology to neurological disorders.

Considering conjugation chemistry, the interplay between cleavable linkers, non-cleavable linkers, and site-specific conjugation methods dictates both the release kinetics of the siRNA moiety and the stability of the overall construct. Cleavable linkers excel in environments with specific intracellular stimuli, while non-cleavable linkers promote prolonged retention. Meanwhile, site-specific approaches ensure homogeneity and facilitate regulatory approval by providing consistent dose-response profiles.

Insights into route of administration underscore the dual prevalence of intravenous and subcutaneous delivery pathways. Intravenous protocols remain dominant for rapid systemic distribution, particularly in acute oncology settings. Conversely, subcutaneous delivery is gaining traction for chronic therapeutic regimens targeting genetic disorders and metabolic conditions, offering enhanced patient convenience and reduced healthcare resource utilization.

Lastly, an exploration by end user and therapeutic area illuminates the convergence of biotechnology innovators, contract research organizations, and pharmaceutical companies in driving modality evolution. Development efforts span genetic disorders-encompassing both common and rare inherited diseases-infectious diseases with bacterial and viral etiologies, and oncology targets that include hematological malignancies as well as solid tumors. These intertwined segmentation lenses illustrate where investment and innovation efforts are coalescing to address unmet medical needs.

Mapping Regional Dynamics Reveals How Americas, EMEA, and Asia-Pacific Are Shaping the Antibody-siRNA Drug Conjugate Ecosystem with Distinct Growth Drivers

Regional dynamics play a decisive role in shaping the antibody-siRNA drug conjugate ecosystem. In the Americas, the presence of large biopharmaceutical hubs, coupled with robust regulatory frameworks and venture capital influx, has catalyzed rapid pipeline progression. Academic-industry collaborations in this region are accelerating translational research, moving candidates from bench to early clinical evaluation at an unprecedented pace.

Meanwhile, in Europe, Middle East & Africa, established regulatory authorities are harmonizing guidelines for advanced therapy medicinal products, thereby fostering a more predictable development environment. Strategic partnerships between academic centers and specialist contract research providers are enhancing localization of conjugation expertise, while emerging markets in the Middle East and Africa are investing in infrastructure to support local manufacturing and clinical trial activity.

In the Asia-Pacific region, government-led incentives and public-private partnerships are driving significant growth. Targeted funding for precision medicine initiatives, combined with expanding biomanufacturing capabilities, is enabling regional players to compete on the global stage. Additionally, burgeoning patient populations and more accessible healthcare systems are providing expansive clinical trial opportunities for novel antibody-siRNA constructs, accelerating the generation of real-world evidence.

Together, these regional insights underscore a complementary mosaic of innovation, regulatory evolution, and market access strategies. By recognizing the distinct strengths and emerging priorities within each geographic corridor, stakeholders can tailor their development and commercialization roadmaps to optimize resource allocation and maximize impact.

Strategic Initiatives and Competitive Landscapes of Leading Innovators Shaping the Future of Antibody-siRNA Drug Conjugate Development and Commercialization

The competitive landscape of antibody-siRNA conjugate development is defined by strategic initiatives from both established biopharmaceutical companies and emerging biotechs. Leading innovators are forging partnerships to combine proprietary antibody scaffolds with specialized RNA interference platforms. These alliances span technology licensing, co-development agreements, and joint ventures, reflecting a collective drive to accelerate time-to-clinic and broaden therapeutic reach.

In parallel, contract research organizations are enhancing their service portfolios to include end-to-end conjugation solutions and integrated ADME (absorption, distribution, metabolism, and excretion) profiling. By investing in automation and high-throughput screening capabilities, these service providers are positioned as critical enablers for clients seeking to streamline preclinical development and iterate rapidly on linker designs and payload variants.

Pharmaceutical heavyweights are also entering the space through targeted acquisitions and strategic investments. By incorporating antibody-siRNA conjugate technologies into established oncology and rare disease franchises, these firms are diversifying their pipelines and hedging against conventional modality attrition. Such moves underscore the modality's perceived potential to address high-value therapeutic areas with significant unmet need.

Collectively, these company-level strategies signal a maturing ecosystem in which collaboration, platform integration, and strategic investments are key determinants of success. Organizations that balance internal innovation with external partnerships will be best positioned to navigate the complex translational pathway and deliver next-generation therapies to patients.

Strategic Imperatives for Industry Leaders to Accelerate Commercial Success and Innovation in Antibody-siRNA Drug Conjugate Development Pipelines

Industry leaders must prioritize agility in their development frameworks to capitalize on the evolving antibody-siRNA conjugate paradigm. Establishing cross-functional teams that integrate process development, analytical sciences, and regulatory affairs from the outset will streamline milestone achievement and mitigate translational risks. By embedding modular conjugation platforms within existing biologics pipelines, organizations can leverage existing manufacturing infrastructure and accelerate commercialization timelines.

In addition, proactive engagement with regulatory authorities to clarify quality and safety expectations is essential. Early submission of analytical method validation data and participation in scientific advice meetings will facilitate alignment on critical quality attributes, reducing the potential for costly resubmissions. Such collaborative approaches not only support efficient regulatory reviews but also demonstrate a commitment to transparency and patient safety.

Finally, forging strategic alliances with contract research and manufacturing partners remains a cornerstone of scaling production while controlling costs. Selecting partners with demonstrated expertise in oligonucleotide synthesis, antibody engineering, and GMP-compliant conjugation workflows will ensure seamless technology transfer. By coupling these technical collaborations with targeted investments in localized manufacturing capabilities, companies can build resilient supply chains that support global launch efforts.

Rigorous Multimodal Research Methodology Integrating Primary Expert Interviews and Secondary Data Sources for Comprehensive Antibody-siRNA Conjugate Market Insights

The research methodology underpinning this analysis integrates a comprehensive blend of primary and secondary data sources to ensure rigor and relevance. Primary insights were gathered through structured interviews with senior executives from biotechnology companies, contract research organizations, and regulatory experts. These qualitative engagements provided an in-depth understanding of conjugation platforms, development challenges, and strategic priorities across the value chain.

Complementing these interviews, secondary research encompassed peer-reviewed literature, patent landscapes, and public disclosures to map the trajectory of technology evolution. Proprietary databases were leveraged to catalog emerging linker chemistries, antibody formats, and siRNA sequence optimizations, while policy documents and regulatory guidance notes informed the assessment of compliance requirements.

Data triangulation and validation steps were employed to reconcile divergent viewpoints and ensure consistency in thematic findings. Statistical analyses of clinical trial registries and pipeline portfolios further corroborated key development trends. This iterative methodology, combining expert opinions with robust desk research, ensures a balanced perspective on current capabilities, future opportunities, and potential barriers in the antibody-siRNA conjugate domain.

Concluding Reflections on the Transformative Potential, Strategic Pathways, and Emerging Opportunities for Antibody-siRNA Drug Conjugates in Therapeutic Landscapes

Antibody-siRNA drug conjugates stand at the nexus of two transformative therapeutic technologies, offering a synergistic approach to disease intervention that transcends the limitations of standalone modalities. Their ability to deliver potent gene-silencing payloads with antibody-level specificity positions them as a versatile platform capable of addressing a broad spectrum of high-unmet-need indications.

The confluence of advanced linker chemistries, site-specific conjugation methods, and robust delivery mechanisms has accelerated the transition of promising candidates into early clinical validation. Concurrently, evolving regulatory frameworks and a maturing service provider ecosystem are reducing development friction and bolstering confidence in commercialization pathways.

Looking ahead, these conjugates will likely expand beyond current oncology and genetic disease applications into new therapeutic frontiers, including immunomodulation and combination regimens. To realize this potential, stakeholders must sustain collaborative innovation, invest in scalable manufacturing, and engage proactively with regulatory authorities. By navigating these strategic imperatives, the industry can unlock the full promise of antibody-siRNA drug conjugates as a new pillar of precision medicine.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Advancements in tumor-targeting antibodies improving siRNA delivery efficacy in solid tumors
• 5.2. Emergence of dual payload antibody-siRNA conjugates tackling multidrug-resistant cancer cells
• 5.3. Optimization of linker technologies driving enhanced stability and release profiles in antibody-siRNA conjugates
• 5.4. Integration of biodegradable polymeric carriers for controlled siRNA release in ADC platforms
• 5.5. Adoption of cryo-EM structural analysis for rational design of antibody-siRNA conjugation sites
• 5.6. Development of bispecific antibodies for co-delivery of siRNA and immunomodulators to tumor microenvironment
• 5.7. Progress in endosomal escape strategies boosting cytosolic siRNA availability in ADC therapies
• 5.8. Regulatory guidelines evolving to standardize antibody-siRNA conjugate characterization and safety testing
• 5.9. Implementation of artificial intelligence in predicting optimal conjugation sites for antibody-siRNA drugs
• 5.10. Strategic partnerships between biotech firms and pharma to accelerate clinical pipelines of antibody-siRNA conjugates

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Antibody-siRNA Drug Conjugates Market, by Target Antibody Type

• 8.1. Introduction
• 8.2. Antibody Fragments
  • 8.2.1. Fab
  • 8.2.2. scFv
• 8.3. Bispecific Antibody
• 8.4. Monoclonal Antibody

9. Antibody-siRNA Drug Conjugates Market, by Conjugation Chemistry

• 9.1. Introduction
• 9.2. Cleavable Linker
• 9.3. Non Cleavable Linker
• 9.4. Site-Specific Conjugation

10. Antibody-siRNA Drug Conjugates Market, by Route of Administration

• 10.1. Introduction
• 10.2. Intravenous (IV)
• 10.3. Subcutaneous (SC)

11. Antibody-siRNA Drug Conjugates Market, by End User

• 11.1. Introduction
• 11.2. Biotechnology Companies
• 11.3. Contract Research Organizations
• 11.4. Pharmaceutical Companies

12. Antibody-siRNA Drug Conjugates Market, by Therapeutic Area

• 12.1. Introduction
• 12.2. Genetic Disorders
  • 12.2.1. Common Genetic Diseases
  • 12.2.2. Rare Genetic Diseases
• 12.3. Infectious Diseases
  • 12.3.1. Bacterial Infections
  • 12.3.2. Viral Infections
• 12.4. Neurological Disorders
• 12.5. Oncology
  • 12.5.1. Hematological Malignancies
  • 12.5.2. Solid Tumors

13. Americas Antibody-siRNA Drug Conjugates Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Antibody-siRNA Drug Conjugates Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Antibody-siRNA Drug Conjugates Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. AbbVie Inc.
  • 16.3.2. Avidity Biosciences Inc.
  • 16.3.3. Biointron Biological Inc.
  • 16.3.4. CD Bioparticles
  • 16.3.5. Dyne Therapeutics, Inc.
  • 16.3.6. Sirnaomics, Inc.
  • 16.3.7. Tallac Therapeutics, Inc.
  • 16.3.8. GlaxoSmithKline plc
  • 16.3.9. Regeneron Pharmaceuticals Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

• FIGURE 1. ANTIBODY-SIRNA DRUG CONJUGATES MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 16. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 18. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ANTIBODY-SIRNA DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 24. ANTIBODY-SIRNA DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 25. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHAI
• FIGURE 26. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHSTATISTICS
• FIGURE 27. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHCONTACTS
• FIGURE 28. ANTIBODY-SIRNA DRUG CONJUGATES MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. ANTIBODY-SIRNA DRUG CONJUGATES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY FAB, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY FAB, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SCFV, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SCFV, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE LINKER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE LINKER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SITE-SPECIFIC CONJUGATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SITE-SPECIFIC CONJUGATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COMMON GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COMMON GENETIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY RARE GENETIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 73. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 74. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 75. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 76. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 77. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 78. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 79. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 80. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 81. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 82. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 83. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 84. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 85. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 86. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 87. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 88. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 89. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 90. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 91. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. AMERICAS ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 93. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 94. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 95. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 96. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 97. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 98. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 99. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 100. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 101. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 102. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 103. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 104. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 105. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 106. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 107. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 108. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 109. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 110. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 111. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 112. UNITED STATES ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 113. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 114. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 115. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 116. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 117. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 118. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 119. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 120. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 121. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 122. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 123. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 124. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 125. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 126. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 127. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 128. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 129. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 130. CANADA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 131. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 132. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 133. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 134. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 135. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 136. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 137. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 138. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 139. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 140. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 141. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 142. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 143. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 144. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 145. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 146. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 147. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 148. MEXICO ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 149. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 150. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 151. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 152. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 153. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 154. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 155. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 156. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 157. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 158. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 159. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 160. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 161. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 162. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 163. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 164. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 165. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 166. BRAZIL ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 167. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 168. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 169. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 170. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 171. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 172. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 173. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 174. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 175. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 176. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 177. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 178. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 179. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 180. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 181. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 182. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 183. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 184. ARGENTINA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 205. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 206. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 207. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 208. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 209. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 210. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 211. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 212. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 213. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 215. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 216. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 217. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 218. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 219. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 220. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 221. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 222. UNITED KINGDOM ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 223. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 224. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 225. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 226. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 227. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 228. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 229. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 230. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 231. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 232. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 233. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 234. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 235. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 236. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 237. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 238. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 239. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 240. GERMANY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 241. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 242. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 243. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 244. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 245. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 246. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 247. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 248. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 249. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 251. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 252. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 253. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 254. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 255. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 256. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 257. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 258. FRANCE ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 259. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 260. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 261. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 262. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 263. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 264. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 265. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 266. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 267. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 268. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 269. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 270. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 271. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 272. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 273. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 274. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 275. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. RUSSIA ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 277. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2018-2024 (USD MILLION)
• TABLE 278. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY TARGET ANTIBODY TYPE, 2025-2030 (USD MILLION)
• TABLE 279. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2018-2024 (USD MILLION)
• TABLE 280. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ANTIBODY FRAGMENTS, 2025-2030 (USD MILLION)
• TABLE 281. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2018-2024 (USD MILLION)
• TABLE 282. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY CONJUGATION CHEMISTRY, 2025-2030 (USD MILLION)
• TABLE 283. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 284. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 285. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 286. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 287. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 288. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 289. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
• TABLE 290. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
• TABLE 291. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 292. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
• TABLE 293. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 294. ITALY ANTIBODY-SIRNA DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 295. SPAIN ANTIBODY-SIRNA DRUG CONJUGATES MARKET